Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment

Nature Materials

Volumn 15, Issue 3, 2016, Pages 353-363

  Conde, João ^a,b   Oliva, Nuria ^a   Atilano, Mariana ^a,c   Song, Hyun Seok ^a,d   Artzi, Natalie ^a,e,f  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c INSTITUT QUÍMIC DE SARRIÀ   (Spain)

^d Korea Basic Science Institute (KBSI)   (South Korea)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; HYDROGELS; SCAFFOLDS (BIOLOGY); TUMORS;

DELIVERY VEHICLE; HYDROGEL SCAFFOLDS; MICROENVIRONMENTS; NATURAL TISSUES; THERAPEUTIC POTENTIALS; TRIPLE HELIXES; TRIPLE-NEGATIVE BREAST CANCERS; TUMOUR SUPPRESSOR;

RNA;

HYDROGEL; MICRORNA; NANOPARTICLE;

ANIMAL; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; CONFORMATION; DRUG EFFECTS; ENDOCYTOSIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HYDROGEL; METABOLISM; MOUSE; NEOPLASM; SCANNING ELECTRON MICROSCOPY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR MICROENVIRONMENT; ENDOCYTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGELS; MICE; MICRORNAS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; NEOPLASMS; NUCLEIC ACID CONFORMATION;

EID: 84959470595     PISSN: 14761122     EISSN: 14764660     Source Type: Journal    
DOI: 10.1038/nmat4497     Document Type: Article

References (50)

1. Kasinski, A. L. & Slack, F. J. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nature Rev. Cancer 11, 849-864 (2011).
2. Li, Z. & Rana, T. M. Therapeutic targeting of microRNAs: Current status and future challenges. Nature Rev. Drug Discov. 13, 622-638 (2014).
3. Yin, H. et al. Non-viral vectors for gene-based therapy. Nature Rev. Genet. 15, 541-555 (2014).
4. Conde, J., Edelman, E. R. & Artzi, N. Target-responsive DNA/RNA nanomaterials for microRNA sensing and inhibition: The jack-of-all-trades in cancer nanotheranostics? Adv. Drug Deliv. Rev. 81, 169-183 (2015).
5. Chen, Y. C., Gao, D. Y. & Huang, L. In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Adv. Drug Deliv. Rev. 81, 128-141 (2015).
6. Yin, P. T., Shah, B. P. & Lee, K. B. Combined magnetic nanoparticle-based microRNA and hyperthermia therapy to enhance apoptosis in brain cancer cells. Small 10, 4106-4112 (2014).
7. Hao, L. L., Patel, P. C., Alhasan, A. H., Giljohann, D. A. & Mirkin, C. A. Nucleic acid-gold nanoparticle conjugates as mimics of microRNA. Small 7, 3158-3162 (2011).
8. Endo-Takahashi, Y. et al. Systemic delivery of miR-126 by miRNA-loaded bubble liposomes for the treatment of hindlimb ischemia. Sci. Rep. 4, 3883 (2014).
9. Chen, Y. C., Zhu, X. D., Zhang, X. J., Liu, B. & Huang, L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 18, 1650-1656 (2010).
10. Anand, S. et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nature Med. 16, 909-914 (2010).
11. Wu, Y. et al. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol. Pharm. 8, 1381-1389 (2011).
12. Mittal, A., Chitkara, D., Behrman, S.W. & Mahato, R. I. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials 35, 7077-7087 (2014).
13. Cheng, C. J. et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518, 107-110 (2015).
14. Shu, D. et al. Systemic delivery of Anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano 9, 9731-9740 (2015).
15. McKiernan, P. J., Cunningham, O., Greene, C. M. & Cryan, S. A. Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology. Int. J. Nanomed. 8, 3907-3915 (2013).
16. Cheng, C. J. & Saltzman, W. M. Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol. Pharm. 9, 1481-1488 (2012).
17. Guo, P. X. The emerging field of RNA nanotechnology. Nature Nanotech. 5, 833-842 (2010).
18. Lee, J. B., Hong, J., Bonner, D. K., Poon, Z. & Hammond, P. T. Self-assembled RNA interference microsponges for efficient siRNA delivery. Nature Mater. 11, 316-322 (2012).
19. Mok, H., Lee, S. H., Park, J.W. & Park, T. G. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nature Mater. 9, 272-278 (2010).
20. Lee, H. et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nature Nanotech. 7, 389-393 (2012).
21. Haque, F. et al. Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. Nano Today 7, 245-257 (2012).
22. Shu, D., Shu, Y., Haque, F., Abdelmawla, S. & Guo, P. X. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nature Nanotech. 6, 658-667 (2011).
23. Jendis, J., Strack, B. & Moelling, K. Inhibition of replication of drug-resistant HIV type 1 isolates by polypurine tract-specific oligodeoxynucleotide TFO A. AIDS Res. Hum. Retroviruses 14, 999-1005 (1998).
24. Moelling, K., Abels, S., Jendis, J., Matskevich, A. & Heinrich, J. Silencing of HIV by hairpin-loop-structured DNA oligonucleotide. FEBS Lett. 580, 3545-3550 (2006).
25. Yoon, K., Hobbs, C. A., Walter, A. E. & Turner, D. H. Effect of a 5′-phosphate on the stability of triple helix. Nucleic Acids Res. 21, 601-606 (1993).
26. Chan, P. P. & Glazer, P. M. Triplex DNA: Fundamentals, advances, and potential applications for gene therapy. J. Mol. Med. 75, 267-282 (1997).
27. Holland, J. A. & Hoffman, D.W. Structural features and stability of an RNA triple helix in solution. Nucleic Acids Res. 24, 2841-2848 (1996).
28. Duca, M., Vekhoff, P., Oussedik, K., Halby, L. & Arimondo, P. B. The triple helix: 50 years later, the outcome. Nucleic Acids Res. 36, 5123-5138 (2008).
29. Foulkes, W. D., Smith, I. E. & Reis, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938-1948 (2010).
30. Nassirpour, R., Mehta, P. P., Baxi, S. M. & Yin, M. J. miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS ONE 8, e62170 (2013).
31. Piovan, C. et al. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol. Oncol. 6, 458-472 (2012).
32. Conde, J., Oliva, N. & Artzi, N. Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance. Proc. Natl Acad. Sci. USA 112, E1278-E1287 (2015).
33. Oliva, N. et al. Regulation of dendrimer/dextran material performance by altered tissue microenvironment in inflammation and neoplasia. Sci. Transl. Med. 7, 272ra211 (2015).
34. Schroeder, A., Levins, C. G., Cortez, C., Langer, R. & Anderson, D. G. Lipid-based nanotherapeutics for siRNA delivery. J. Int. Med. 267, 9-21 (2010).
35. Francois, J. C. et al. Sequence-specific recognition and cleavage of duplex DNA via triple-helix formation by oligonucleotides covalently linked to a phenanthroline copper chelate. Proc. Natl Acad. Sci. USA 86, 9702-9706 (1989).
36. Chiou, C. C., Chen, S.W., Luo, J. D. & Chien, Y. T. Monitoring triplex DNA formation with fluorescence resonance energy transfer between a fluorophore-labeled probe and intercalating dyes. Anal. Biochem. 416, 1-7 (2011).
37. Wan, C. H., Cui, M., Song, F. R., Liu, Z. Q. & Liu, S. Y. Evaluation of effects of bivalent cations on the formation of purine-rich triple-helix DNA by ESI-FT-MS. J. Am. Soc. Mass Spectrom. 20, 1281-1286 (2009).
38. Carlson, R. D., Olins, A. L. & Olins, D. E. Urea denaturation of chromatin periodic structure. Biochemistry 14, 3122-3125 (1975).
39. Ha, M. & Kim, V. N. Regulation of microRNA biogenesis. Nature Rev. Mol. Cell Biol. 15, 509-524 (2014).
40. Conner, S. D. & Schmid, S. L. Regulated portals of entry into the cell. Nature 422, 37-44 (2003).
41. Conde, J. et al. 15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi Therapeutics. Nano Today http://dx.doi.org/10.1016/j.nantod.2015.06.008 (in the press).
42. Kitchens, K. M., Kolhatkar, I. B., Swaan, P.W. & Ghandehari, H. Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Ceco-2 cells. Mol. Pharm. 5, 364-369 (2008).
43. Jones, A. T. Macropinocytosis: Searching for an endocytic identity and role in the uptake of cell penetrating peptides. J. Cell Mol. Med. 11, 670-684 (2007).
44. Linares, J. et al. Endocytic mechanisms of graphene oxide nanosheets in osteoblasts, hepatocytes and macrophages. ACS Appl. Mater. Interfaces 6, 13697-13706 (2014).
45. Iversen, T. G., Skotland, T. & Sandvig, K. Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies. Nano Today 6, 176-185 (2011).
46. Segovia, N. et al. Hydrogel doped with nanoparticles for local sustained release of siRNA in breast cancer. Adv. Healthc. Mater. 4, 271-280 (2015).
47. Sledge, G.W. et al. Past, present, and future challenges in breast cancer treatment. J. Clin. Oncol. 32, 1979-1986 (2014).
48. Sparano, J. A. et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med. 358, 1663-1671 (2008).
49. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
50. Oliva, N. et al. Natural tissue microenvironmental conditions modulate adhesive material performance. Langmuir 28, 15402-15409 (2012).